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collected on demographic and clinical parameters and patients were asked to com-
plete the 5-level EQ-5D health-related quality of life (HRQL) questionnaire. Contin-
uous variables were summarized with medians and standard deviations and com-
pared using Students t-test. Categorical variables were summarized with
proportions. P-values 0.05 were taken to indicate significance. Data analyzed
using SPSS-19. RESULTS: There were 31 (76%) males. 38 (93%) had contracted HCV
through intravenous drug use. Median HRQL utility was 0.71 (/ 0.32). Mean HRQL
utilities were significantly lower in patients with cirrhosis (0.38 versus 0.67, p
0.03) and in patients with CD4 counts200 (0.41 versus 0.70, p0.005). Mean HRQL
scores were found to be higher in patients who had received HCV treatment than
those who did not (0.71 versus 0.52 ) although this did not reach statistical signifi-
cance (p 0.06). CONCLUSIONS: HRQL was found to be reduced in patients with
advanced HIV and HCV. Since HCV evolution to cirrhosis has been shown to reduce
quality of life, the importance of treatment of both HIV and HCV infection to pre-
vent progression of liver disease is emphasized.
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OBJECTIVES: Understand physician and patient perspectives with respect to pa-
tient involvement in treatment decisions and the perceived impact on patient
outcomes in SLE. METHODS: This was a cross-sectional U.S survey of independent
(geographically diverse) samples of practicing rheumatologists (with 3yrs of SLE
experience) and adult SLE patients recruited from panels & clinics. Study partici-
pants completed a one-time web-survey covering perceptions of SLE-manage-
ment, patient-physician-communication and expectations. Analysis included de-
scriptive statistics and subgroup comparisons using chi-square and t-tests.
RESULTS: 218 physicians (Caucasian 68%; African-American 1%; mean age 49ys)
and 166 patients (Caucasian 61%; African-American 30%; mean-age 47ys) com-
pleted the survey as of April 2012. Overall, 61% and 76% of physicians and patients,
respectively, reported high-patient-involvement (often/very often) in treatment
decisions. Physicians and patients in high-patient-involvement groups (vs. low-
patient-involvement groups): a) reported greater satisfaction with physician-pa-
tient interactions (physicians: 8.1vs.7.5,p0.12; patients: 9.1vs.6.3,p0.001) and b)
were more likely to discuss daily impacts all/most of the time (physicians:
70%vs.54%,p0.002; patients:76%vs.55%,p0.002). Among physicians, no differ-
ences were observed between high-vs.-low-patient-involvement groups in being
hopeful about patient future (95%vs.95%) and ratings of their bedside manner
(78%vs.75% warm/very-warm); whereas, among patients in high-vs.-low-involve-
ment groups, these ratings were 82%vs.67% (p0.001) and 72%vs.41% (p0.001),
respectively. More patients in high-involvement group reported not missing a
dose/appointment since treatment-initiation (59%vs.50%,p0.36) and setting clear
goals with their physicians (78%vs.26%,p0.003); more high-involvement patients
also reported their SLE had a high/very-high impact on their QOL (66%vs.53%,p
0.01). Those who believe that patient involvement in treatment decisions im-
proves outcomes ‘a lot’ differed significantly (p0.03) in high-vs.-low-patient-in-
volvement groups among physicians (57%vs.0%) and patients (58%vs.35%).
CONCLUSIONS:Rheumatologists and SLE-patients reporting high-patient-involve-
ment in treatment related decisions were relatively more satisfied with their inter-
actions and had a positive outlook on future and outcomes. Further research is
warranted to assess factors influencing these attitudes and their impact on patient
outcomes in clinical practice.
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OBJECTIVES: Lifelong treatment for many chronic conditions, such as atrial fibril-
lation (AF), involves complex care pathways with numerous points of interaction
between patients and health care providers. The EUPS-AF was conducted to assess
patient-reported levels of satisfaction with current management of AF in Europe.
METHODS: The EUPS-AF questionnaire was adapted from the 2008 Common-
wealth Fund International Health Policy Survey of Chronically Ill Adults by includ-
ing additional questions capturing AF-specific patient characteristics and treat-
ment preferences. Computer-assisted telephone interviews were conducted
between February and July 2011 via randomized digital dialling covering the entire
adult populations of France, Germany, Italy, Spain and the UK. Questions covered
the following nine domains: overview of the health system; ease of health care
access; relationship with care providers; hospital experience; use of medication,
coordination of polymedication and cost; safety concerns; experience with other
chronic diseases; access to information; financial burden. RESULTS: Of the 340,476
individuals contacted, 1.08% were identified with AF; 1793 were eligible for inclu-
sion after screening; 321 (17.6%) declined to participate. Interviews were conducted
in 1507 adults (50% women); mean age 70 years. On average, 43% lived in a village
or rural location. Mean number of people per household was two; 56% had an
income below average; 54% had been hospitalized during the past 2 years, with an
average of 2.2 comorbidities and 5.7 prescription medications. Overall satisfaction
rates ranged from 37% (Italy) to 55% (UK). CONCLUSIONS: The EUPS-AF, under-
taken uniquely from a patient perspective before the introduction of novel oral
anticoagulants into clinical practice, provides additional and complementary data
to clinical trials and registries and allows the detection of international variations
in satisfaction levels of patients with AF. This can promote research into the causes
of variation, focus where innovations may be beneficial, and may reduce inequal-
ities in standards of care if these underlie the variations.
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OBJECTIVES: Evaluate from the patient perspective a systemic anti-cancer therapy
homecare service METHODS: A pilot project was undertaken at the Royal Surrey
County Hospital, in England, where three oral anti-cancer drugs were prescribed by
hospital clinicians but dispensed by a homecare company. Patients were asked at
the point of recruitment by the oncology pharmacists at the Royal Surrey County
Hospital whether they were willing to take part in the homecare project. A ques-
tionnaire was developed with the input of patients. The questionnaire was tested
with five patients for acceptability and their comments fed into the design of the
final questionnaire. The questionnaire consisted of open and closed questions and
was sent out by the homecare company to all patients who were receiving home-
care six months after the start of the project. The questionnaire was returned to the
Cancer Network Pharmacist for analysis. RESULTS: Ninety-one patients were ap-
proached to take part in the project by the oncology pharmacy staff at the Royal
Surrey County Hospital. When first approached 78 patients were prepared to take
part in project, some declined and others required time to decide. The question-
naire was sent out to 85 patients. A total of 49 questionnaires were returned but
some were not included in the analysis as they were from deceased patients or had
been completed by a carer. Of the 40 questionnaires analysed 34 patients were
willing to continue to receive their medication via homecare, 18 specifically stated
a benefit was not waiting at the hospital for their medicine and 4 patients specifi-
cally stated they preferred to receive their medicines via homecare than from a
community pharmacy. CONCLUSIONS: Patients find homecare acceptable for the
delivery of systemic anti-cancer therapy and some prefer it to waiting at hospital
for their medication or going to a community pharmacy to have their prescription
dispensed.
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OBJECTIVES: To analyze the willingness for shared decision making (SDM) of rheu-
matologic patients. METHODS: All rheumatic patients assisted were invited to
participate in this cross-sectional study. A three parts questionnaire was applied
(demographic, clinical data and 3 scenarios that simulate a clinical encounter). The
scenarios presented the 3 typical steps of a consultation, according to SDM process:
1) Diagnostic statement; 2) treatment options discussion; 3) decision-making. For
each step, interviewee was argued 3 questions: a) To identify weather each part
was similar to his/her clinical encounter or not; b) to define whether SDM can be a
feasible approach; and c) to answer if he/she wanted to be assisted in SDM process,
justifying it. Descriptive and multiple correspondence analysis (MCA) techniques
were performed to explore data.RESULTS:Demographic data (N160): 89% female,
60%  8 years of school, 48.8% had  4 years of diagnosis and 30%,  8 years of
diagnosis. Scenario one: 97% would like to have SDM approach on their real clinical
practice, justified according to ‘communication empowerment’ (75%) and ‘pa-
tients’ right relationship’ (23%). Scenario two: 65% declared that they like SDM
purpose, justifying it according to ‘communication empowerment’ (63%)’. Scenario
three: 65% of the participants never took part in the decision process. However, 98%
would like to do it, justifying according to ‘patients’ right relationship’ (30%), and
‘communication empowerment’ (28%) but 13% answered that the whole decision
belongs to the physician. MCA plot illustrates that for diagnostic statement ‘com-
munication empowerment’ correlates to low literacy. To understand treatment
option, communication empowerment and patient’s right was correlated with
those who had  4 years of diagnosis; and  two rheumatic conditions.
CONCLUSIONS: Communication empowerment and patient’s right were the most
common reasons for the willingness for SDM.
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OBJECTIVES: To develop a mapping algorithm for converting the prostate cancer
specific Health-Related Quality of Life (HRQoL) instrument FACT-P (Functional As-
sessment of Cancer Therapy–Prostate) to the preference-based EQ-5D (Euro-QoL
5D) instrument for measuring health status. METHODS: Data were obtained from
the phase 3 placebo-controlled AFFIRM trial of enzalutamide-proposed INN
(MDV3100) in men with metastatic castration-resistant prostate cancer previously
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